EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): Annual Results The invitation to the 20th Ordinary Shareholders' Meeting on 18 June 2021 has been sent to the shareholders of HBM Healthcare Investments today. In accordance with the Ordinance 3 on Measures to Combat the Coronavirus (COVID-19), issued by the Swiss Federal Council, this year's Ordinary Shareholders Meeting is not held in the usual form, i.e. the shareholders are not permitted to participate in person. The Board of Directors has resolved in accordance with Art. 27 of the said Ordinance, that the shareholders may exercise their rights exclusively through the independent proxy by way of written or electronic instruction and power of attorney. The detailed invitation with all motions of the Board of Directors is enclosed and displayed on the Company's website www.hbmhealthcare.com/en/news. Agenda for the 20th Ordinary Shareholders' Meeting on 18 June 2021 1. Statutory financial statements and group financial statements 2020/2021; reports of the 2. Discharge from liability of the members of the Board of Directors and Management 3. Appropriation of results 4. Elections regarding the Board of Directors 5. Compensation to the Board of Directors and to the Management 6. Appointment of auditors 7. Appointment of independent proxy-holder 8. Reduction of share capital: partial payback of nominal value 9. Miscellaneous
HBM Healthcare Investments also published today its Annual Report 2020/2021 on the Company's website www.hbmhealthcare.com/en/investors/financial-reports. Contact About HBM Healthcare Investments HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN). Disclaimer The publication is for information purposes only and does not constitute an offer to sell or a solicitation to buy or subscribe for securities. This news release does not constitute a prospectus within the meaning of Art. 35ff FinSA, or securities prospectus in the sense of the German securities prospectus law. This news release and the information contained therein is not intended for distribution to the United States of America (USA) or within the USA and may not be distributed or forwarded to US persons (including legal persons) or to publications with a general distribution in the USA. This news release is not an offer or solicitation to buy securities in the United States. HBM Healthcare Investments AG's securities were not issued in accordance with the U.S. U.S. securities laws, and may not be sold, offered for sale, or delivered in the U.S. or to U.S. individuals without prior registration or without a registration exemption. Some information quoted was obtained from external sources HBM considers to be reliable. HBM cannot guarantee the adequacy, accuracy, timeliness or completeness of or be held responsible or liable for errors of fact regarding such data and information obtained from third parties, and this data may change with market conditions. End of ad hoc announcement |
Language: | English |
Company: | HBM Healthcare Investments AG |
Bundesplatz 1 | |
6300 Zug | |
Switzerland | |
Phone: | +41438887171 |
Fax: | +41438887172 |
E-mail: | info@hbmhealthcare.com |
Internet: | https://www.hbmhealthcare.com |
ISIN: | CH0012627250 |
Valor: | 1262725 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 1201131 |
End of Announcement | EQS Group News Service |
|
1201131 27-May-2021 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.